The US Food and Drug Administration’s approval of the first CAR (chimeric antigen receptor) T cell therapy was a key advancement in cancer therapy. As new T cell therapies continue to progress clinically, the need for autologous T cell manufacturing technologies that cost-effectively scale from pre-clinical to commercial production is becoming critical.
Corning understands your need for clinical cell expansion platforms that scale from research to commercial production. Leveraging our expertise in research-scale immune cell culture, we partner with cutting-edge US cancer centers to develop technologies designed to reduce manufacturing time and drive down production costs.
